CLINICAL_TRIALS trial_result · 2013-10-23

Clinical Trial Update: IPI-504 in NSCLC Patients With ALK Translocations [Phase 2]

Phase 2 study of IPI-504 (retaspimycin hydrochloride) in ALK-translocated non-small cell lung cancer was terminated; results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Massachusetts General Hospital | Conditions: Lung Cancer, Stage IIIb Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2013-10-23